Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Est. Listeners
Based on iTunes & Spotify (publisher stats).
- Per-Episode Audience
Est. listeners per new episode within ~30 days
10,001 - 25,000 - Monthly Reach
Unique listeners across all episodes (30 days)
25,001 - 75,000 - Active Followers
Loyal subscribers who consistently listen
15,001 - 40,000
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Rewriting Disease Biology Through LSD1 Inhibition with Oryzon's Carlos Buesa, Ph.D.
Apr 23, 2026
23m 27s
Advancing Early Detection in Rare Cancers with Catriona Jamieson, M.D., Ph.D.
Apr 9, 2026
20m 46s
Regulatory Flexibility in CGT: Key Shifts and Implications with Monika Swietlicka
Mar 26, 2026
27m 18s
Scaling CRISPR for Rare Disease with Aurora Therapeutics' Dr. Edward Kaye
Mar 12, 2026
28m 04s
Simplifying Friction in Cell Therapy Clinical Trials with Dr. Panteli Theocharous
Feb 26, 2026
34m 24s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 4/23/26 | Rewriting Disease Biology Through LSD1 Inhibition with Oryzon's Carlos Buesa, Ph.D. | We love to hear from our listeners. Send us a message. On Episode 127 of Cell & Gene: The Podcast, Carlos Buesa, Ph.D., Founder and Chairman of the Board at Oryzon talks to Host Erin Harris about how targeting LSD1 is unlocking new treatment approaches across oncology, CNS disorders, and sickle cell disease, with promising early clinical data and a strategy grounded in precision epigenetics. Subscribe to the podcast! Apple | Spotify | YouTube Visit my website: Cell &... | 23m 27s | ||||||
| 4/9/26 | Advancing Early Detection in Rare Cancers with Catriona Jamieson, M.D., Ph.D. | We love to hear from our listeners. Send us a message. On episode 126 of Cell & Gene: The Podcast, Host Erin Harris welcomes Catriona Jamieson, M.D., Ph.D, Director of the UC San Diego Sanford Stem Cell Institute and Professor of Medicine at the School of Medicine. They explore how shifting the medical mindset from “common horses” to rare “zebras” is unlocking earlier detection and more effective treatment of diseases like myelofibrosis. Dr. Jamieson explains how subtle, often overlooked ... | 20m 46s | ||||||
| 3/26/26 | Regulatory Flexibility in CGT: Key Shifts and Implications with Monika Swietlicka | We love to hear from our listeners. Send us a message. On episode 125 of Cell & Gene: The Podcast, Host Erin Harris talks to Halloran Consulting Group's Monika Swietlicka to discuss how the FDA is increasing flexibility in cell and gene therapy development without lowering evidentiary standards, emphasizing a risk-based, holistic approach. They also explore what this means for developers, from platform strategies and global regulatory divergence to the growing role of patient advocacy and... | 27m 18s | ||||||
| 3/12/26 | Scaling CRISPR for Rare Disease with Aurora Therapeutics' Dr. Edward Kaye | We love to hear from our listeners. Send us a message. On episode 124 of Cell & Gene: The Podcast, Aurora Therapeutics' CEO Dr. Edward Kaye discusses the company’s strategy for translating CRISPR gene editing into scalable, commercially viable medicines for rare diseases. Aurora is initially targeting phenylketonuria (PKU) using a platform approach that leverages shared components, such as lipid nanoparticles and base editors, while customizing guide RNAs for specific mutations. Dr. Kaye ... | 28m 04s | ||||||
| 2/26/26 | Simplifying Friction in Cell Therapy Clinical Trials with Dr. Panteli Theocharous | We love to hear from our listeners. Send us a message. In episode 123 of Cell & Gene: The Podcast, Host Erin Harris talks to Dr. Panteli Theocharous, FIBMS, M.S., Ph.D., FRCPath, about the patient journey in cell therapy trials. They pinpoint key friction points, such as delayed referrals, unpredictable vein-to-vein timelines, and burdensome long-term follow-up, while sharing actionable strategies for simplification. These strategies range from upstream trial design and streamlined consen... | 34m 24s | ||||||
| 2/12/26 | Inside a Breakthrough HER2 Immunotherapy for PMO with OS Therapies’ Paul Romness | We love to hear from our listeners. Send us a message. In episode 122 of Cell & Gene: The Podcast, Host Erin Harris talks to Paul Romness, CEO of OS Therapies, to learn the company’s mission to address the severe unmet need in pulmonary metastatic osteosarcoma (PMO), a rare pediatric cancer with no established standard of care once it metastasizes. Romness explains how OS Therapies’ off-the-shelf HER2-targeted immunotherapy aims to significantly improve outcomes by stimulating a robust im... | 14m 20s | ||||||
| 1/29/26 | Building Safer CRISPR Medicines for CVD with Scribe Therapeutics' Benjamin Oakes | We love to hear from our listeners. Send us a message. In episode 121 of Cell & Gene: The Podcast, Host Erin Harris talks to Scribe Therapeutics' CEO and Co-Founder Benjamin Oakes about building next‑generation CRISPR and epigenetic editing tools to move genetic medicine beyond rare disease into common cardiometabolic indications. Oakes shares Scribe’s engineered CasX platform and epigenetic silencers, preclinical data from its various programs, and why exquisite specificity and low-dose ... | 30m 03s | ||||||
| 1/15/26 | Advancing Off-the-Shelf CRISPR CAR-T Therapies into the Community Setting with Caribou Biosciences' Rachel Haurwitz | We love to hear from our listeners. Send us a message. Welcome to episode 120 of Cell & Gene: The Podcast. Host Erin Harris is joined by Rachel Haurwitz, CEO of Caribou Biosciences, to discuss the company’s progress in developing CRISPR-edited, off-the-shelf CAR-T therapies for hematologic malignancies. Their conversation centers on Vispacell, Caribou’s allogeneic CD19 CAR-T for second-line large B-cell lymphoma. Haurwitz explains how Caribou has systematically optimized its allogeneic pl... | 19m 32s | ||||||
| 1/9/26 | The Editors' Roundtable: A 2025 Retrospective of the Life Science Industry | We love to hear from our listeners. Send us a message. We’re sharing this Better Biopharma episode on Cell & Gene: The Podcast because Better Biopharma is a sister show in the Life Science Connect family, and this conversation touches so many of the same challenges, pressures, and big-picture shifts our audience is thinking about right now. CGT doesn’t live in a bubble, and neither do the people building it. So we wanted to bring this wider, cross-industry conversation straight to you. Su... | 1h 22m 27s | ||||||
| 1/1/26 | Developing Itvisma for Broad-Range Treatment of SMA with Novartis' Dr. Norman Putzki | We love to hear from our listeners. Send us a message. In episode 119 of Cell & Gene The Podcast, Host Erin Harris talks to Dr. Norman Putzki, Global Head Clinical Development, Novartis, about the FDA approval of Itvisma, now the only gene replacement therapy approved for children, adolescents, and adults with spinal muscular atrophy (SMA). Dr. Putzki walks us through the six-year development journey behind the STEER and STRENGTH Phase 3 programs. And we explore what the expanded age-rang... | 21m 05s | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 12/18/25 | Turning the Tumor Microenvironment Against Cancer with MGB's Alexander Cryer, Ph.D. | We love to hear from our listeners. Send us a message. In Episode 118, Host Erin Harris talks to Alexander Cryer, Ph.D., Instructor in Medicine at Mass General Brigham, about a proof of concept strategy that reprograms tumor cells with mRNA lipid nanoparticles to overactivate the cGAS-STING pathway, forcing cancer cells to produce and export large amounts of the innate immune agonist cGAMP to stimulate surrounding immune cells and drive anti-tumor immunity. Dr. Cryer explains the basic biolog... | 16m 25s | ||||||
| 12/4/25 | Building Patient-Driven Culture and Leadership Resilience in CGT with Paul Perreault | We love to hear from our listeners. Send us a message. On episode 117, Host Erin Harris welcomes Paul Perreault, Strategic Advisor, Board Member and former CEO of CSL, who shares insights from his decade leading the company through global expansion and the COVID-19 pandemic. Perreault highlights the importance of patient-centered culture, strategic focus, and adaptive leadership for cell and gene therapy innovators. He offers practical advice on building a values-driven culture that connects ... | 18m 18s | ||||||
| 11/20/25 | Treating Inherited Retinal Disorders with Ocugen's Dr. Arun Upadhyay | We love to hear from our listeners. Send us a message. In episode 116 of Cell & Gene: The Podcast, Host Erin Harris talks to Dr. Arun Upadhyay, Chief Scientific officer, Head of Research and Development at Ocugen to discuss how the company’s modifier gene therapy platform is redefining treatment possibilities for inherited retinal diseases such as retinitis pigmentosa, Stargardt disease, and geographic atrophy. Dr. Upadhyay explains how Ocugen’s gene-agnostic approach differs from traditi... | 26m 56s | ||||||
| 11/6/25 | Advancing Hematology and Cell Therapy Innovation with AstraZeneca's Aliya Omer | We love to hear from our listeners. Send us a message. Episode 115 of Cell & Gene: The Podcast features Host Erin Harris' talk with Aliya Omer, Vice President and Global Head of Hematology and Cell Therapy at AstraZeneca. Omer shares valuable insights from her rich experience leading cell therapy development across multiple top companies. She highlights the critical importance of collaboration by breaking down silos across research, manufacturing, regulatory, and commercial teams to deliv... | 34m 02s | ||||||
| 10/23/25 | Advancing Allogeneic Cell Therapy for SCI and Blindness with Lineage's Brian Culley | We love to hear from our listeners. Send us a message. On episode 114 of Cell & Gene: The Podcast, Host Erin Harris talks to Brian Culley, CEO of Lineage Cell Therapeutics, about advancing cell therapy beyond oncology and into transformative treatments for conditions such as spinal cord injury and blindness. Culley shares how Lineage’s allogeneic, off-the-shelf approach, anchored by its OPC1 program, aims to replace lost or damaged cells to restore function, starting with patients who hav... | 26m 23s | ||||||
| 10/9/25 | How AI and ML Drive iPSC Quality with Aspen Neuroscience's Thorsten Gorba, Ph.D. | We love to hear from our listeners. Send us a message. Welcome to Episode 113 of Cell & Gene: The Podcast. Host Erin Harris is joined by Thorsten Gorba, Ph.D., VP Process Development at Aspen Neuroscience to explore how the company is advancing the field of cell therapy manufacturing. Aspen Neuroscience stands at the forefront of integrating machine vision and AI/ML to assess induced pluripotent stem cell (iPSC) colony quality by offering a transformative approach to move beyond the subje... | 21m 38s | ||||||
| 9/25/25 | Inside Sanofi’s Genomic Medicine Vision with Mike Quigley, Ph.D. | We love to hear from our listeners. Send us a message. On episode 112 of Cell & Gene: The Podcast, Michael Quigley, Ph.D., Chief Scientific Officer and Global Head of Research at Sanofi talks to Host Erin Harris about the establishment of Sanofi’s dedicated Genomic Medicine Unit (GMU). Dr. Quigley emphasizes in vivo delivery and process optimization to improve patient experience, scalability, and global access. They discuss the importance of partnerships with academia, industry, and regul... | 24m 15s | ||||||
| 9/11/25 | Engineering Off-the-Shelf Cell Therapies for Cancer & Autoimmune Disease with Ernexa Therapeutics' Sanjeev Luther | We love to hear from our listeners. Send us a message. On episode 111 of Cell & Gene: The Podcast, Host Erin Harris talks to Ernexa Therapeutics' President and CEO, Sanjeev Luther, about how the company is advancing cell therapy innovation for cancer and autoimmune disease through engineered induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs). Luther shares how Ernexa’s synthetic, standardized, off-the-shelf iMSCs are designed to overcome historic hurdles in MSC therapy, ... | 20m 58s | ||||||
| 8/29/25 | What Changes to FDA and CBER Mean for the Future of CGT with Daniela Drago | We love to hear from our listeners. Send us a message. This is Episode 4 of "FDA Fridays," a special series from Cell & Gene: The Podcast, Chief Editor Erin Harris speaks with regulatory affairs expert Daniela Drago, Partner, NDA Partners, about how shifting FDA and CBER priorities under the current administration could influence the trajectory of cell and gene therapy development. From the impact of leadership changes and evolving policy directives to the role of funding allocations and ... | 23m 15s | ||||||
| 8/28/25 | Inside CRISPR-GPT with Yuanhao Qu | We love to hear from our listeners. Send us a message. In this episode of Cell & Gene Podcast episode, Host Erin Harris talks to Stanford School of Medicine Ph.D. student, Yuanhao Qu, about his work developing CRISPR-GPT, an AI-driven multi-agent system designed to automate genetic experimental design and data analysis, making CRISPR experiments more efficient and accessible, even for non-experts. Qu explains how CRISPR-GPT addresses key challenges such as guide design, delivery methods, ... | 20m 16s | ||||||
| 8/22/25 | Barriers, Breakthroughs, and Building Access in Pediatric CGTs with Bambi Grilley, Ph.D. | We love to hear from our listeners. Send us a message. This is Episode 3 of "FDA Fridays," a 4-week special series from Cell & Gene: The Podcast. Host Erin Harris talks to Bambi Grilley, Ph.D., Professor of Pediatrics and the Director of Clinical Research and Early Product Development for the Center of Cell and Gene Therapy (CAGT) at Baylor College of Medicine and Chief Regulatory Officer for ISCT, a leading expert at the forefront of pediatric cell and gene therapy. Dr. Grilley shares he... | 45m 40s | ||||||
| 8/15/25 | Defining Product Roles and Navigating FDA Approval with Monika Swietlicka | We love to hear from our listeners. Send us a message. Episode 2 of FDA Fridays, the special series from Cell & Gene: The Podcast, features Host Erin Harris' discussion with regulatory expert Monika Swietlicka, Principal, Regulatory Strategy, Halloran Consulting Group about the key strategies and challenges in navigating FDA regulation for cell and gene therapies. Their conversation covers the importance of defining a therapy’s intended role (curative, chronic, or adjunctive) early in dev... | 38m 30s | ||||||
| 8/14/25 | Advancing Gene Therapy for FTD with Passage Bio's Dr. Will Chou | We love to hear from our listeners. Send us a message. In Episode 109 of Cell & Gene: The Podcast, Host Erin Harris talks to Will Chou, M.D., CEO of Passage Bio about the promise and challenges of developing gene therapies for frontotemporal dementia (FTD), a neurodegenerative disease with strong genetic underpinnings. Dr. Chou discusses the biological basis of FTD and the complex scientific, manufacturing, and regulatory hurdles that come with targeting the brain. They discuss the latest... | 24m 15s | ||||||
| 8/8/25 | FDA Fridays: Advancing Communication and Consistency in CGT Regulation with Kaye Spratt | We love to hear from our listeners. Send us a message. This is Episode 1 of a special series of Cell & Gene: The Podcast, "FDA Fridays." This first episode features Host, Erin Harris' conversation with Kate Spratt, Strategic and Non-Clinical Regulatory Consultant at Spratt Advanced Cell & Gene Therapy Regulatory Consulting. Spratt emphasizes the importance of early and continuous engagement with regulatory authorities, especially through structured meetings like INTERACT and pre-IND s... | 47m 14s | ||||||
| 7/31/25 | Navigating the Journey to Safer Stem Cell Therapies with Orca Bio's Nate Fernhoff | We love to hear from our listeners. Send us a message. Cell & Gene: The Podcast Host, Erin Harris, talks to Orca Bio CEO and Co-Founder Nathaniel Fernhoff as he recounts the company’s origins and evolution, tracing its roots to pioneering stem cell research at Stanford University and Dr. Irv Weissman's lab. Seeking to create safer, more effective cures for blood cancers such as AML, ALL, and MDS, Orca Bio developed high-precision cell therapies that utilize purified regulatory T cells and... | 33m 17s | ||||||
Showing 25 of 133
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
16 placements across 16 markets.
Chart Positions
16 placements across 16 markets.